Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes

BACKGROUND: Although glargine and detemir are both FDA-approved in the U.S. as long-acting insulin analogues, inherent differences in the insulins may lead to varying outcomes. This study examined changes in clinical measures and associated costs for veterans with type 2 diabetes on insulin therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Asias, Bernadette D., Stock, Eileen M., Small, Nancy L., Getchell, Katerine E., Patel, Jagruti R., Krause, Jennifer D., Cavness, Staci, Dzenowski, Cassidy L., Ta, Mia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482160/
https://www.ncbi.nlm.nih.gov/pubmed/26120575
http://dx.doi.org/10.1186/s40200-015-0180-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482160/
https://www.ncbi.nlm.nih.gov/pubmed/26120575
http://dx.doi.org/10.1186/s40200-015-0180-z

Ejemplares similares